Acute Kidney Injury (AKI) is a critical condition often encountered in pediatric intensive care units (PICUs), characterized by a rapid decline in kidney function. Early diagnosis and intervention are crucial to improving outcomes in these vulnerable patients. Serum Cystatin C (CysC), a promising biomarker, has emerged as a potential diagnostic tool for detecting AKI in children. Unlike traditional markers such as serum creatinine, CysC is less influenced by age, gender, and muscle mass, making it a more reliable indicator of kidney function in pediatric populations. This review aims to explore the role of Serum Cystatin C in the early detection, diagnosis, and monitoring of AKI in children within the PICU setting. The potential advantages, limitations, and clinical implications of CysC as a biomarker are discussed, along with recent research findings highlighting its utility in pediatric AKI. Ultimately, understanding the role of CysC could lead to improved outcomes by enabling timely interventions and better management strategies for pediatric patients at risk of AKI.